Format

Send to

Choose Destination
Trends Pharmacol Sci. 2000 Sep;21(9):346-53.

CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics.

Author information

1
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. akopin@msn.com

Abstract

Polymorphisms in G-protein-coupled receptors can alter drug affinity and/or activity. In addition, genetic differences in amino acid sequences can induce ligand-independent signaling, which in turn can lead to disease. With growing efforts in the field of pharmacogenomics, it is anticipated that polymorphism-induced alterations in drug and/or receptor function will be a focus of increasing concern during the course of future drug-development efforts. In this review, the spectrum of pharmacological consequences that result from polymorphisms in the cholecystokinin CCK2 receptor will be discussed, thereby illustrating emerging themes in pharmacogenomics.

PMID:
10973088
DOI:
10.1016/s0165-6147(00)01526-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center